Polypeptide With Localisation/Targeting Motif TRIZ Cases

Engineered allogeneic tumor cells express OX40L, CD27L, and CD28L to counteract MHC downregulation and immunosuppressive cytokines.

Modifying the Cas12a protein with a myc-NLS tag and an enhancer reduces off-target effects while improving indel efficiency for precise genome editing.

NK receptor-based CARs improve specificity and reduce off-target effects through segmented signaling domains.

CAR constructs with anti-CD276 scFvs eliminate solid tumor cells while improving patient survival rates.

ApoB-fused single chain antibodies selectively clear 3-repeat tau accumulation in the brain, resolving specificity issues of prior total tau immunotherapies.

CasX CRISPR systems knock down PTBP1 expression to address neurological diseases and cancers lacking effective genetic-based solutions.

Measuring fold changes in tumor burden indicators identifies patients at risk for severe cytokine release syndrome prior to cell therapy administration.

Optimized amino acid sequences with proline residues preserve structural integrity and solubility, enabling efficient intracellular delivery of bound cargo.

Multi-target CAR-T therapy eliminates CXCR5-expressing lymphoma while sparing normal hematopoietic cells.

Oncolytic herpes simplex virus infects solid tumors to express glycoprotein D, enabling chimeric antigen receptor T cells to overcome antigen heterogeneity.

Modified T cells express IL-7 via an inducible promoter, reducing systemic toxicity while maintaining antitumor efficacy.

Co-administered CAR-T and APCs resolve insufficient inflammatory response activation in solid tumors.

Segmented Cas9 and sgRNA components enable precise RNA tracking while avoiding unwanted DNA modifications.

Segmented bacterial production and intermediary pro-region processing boost rhNGF yield to 78 mg/L while ensuring correct folding.

Separate signaling molecules enable precise activation while preventing uncontrolled expansion and cytokine storm toxicity.

Dual CAR T cells resolve limited persistence by targeting B-cell and solid tumor antigens simultaneously.

Segmented immunotoxin constructs eliminate PD-1 positive cells while sparing naive lymphocytes, resolving autoimmune treatment side effects.

Genetically modified animals express human TSLP and TSLPR proteins to create a biologically relevant testing platform.

Fusion polypeptide targets conserved coronavirus envelope protein to overcome high viral mutation rates.

Viral-like particles shield antigens from gastrointestinal degradation to induce robust mucosal immunity against coronaviruses.

A peptide called SD1 binds to Sema3E, blocking its interaction with PlexinD1.

Engineered T cell receptor targets KRAS G12V mutation peptide via HLA binding, sparing wild-type RAS proteins to reduce side effects.

Engineered immune cells combine chimeric antigen receptors with Fc fusion polypeptides to enhance antigen recognition and activation.

LAMP-fused DNA vaccine antigens direct allergen processing to lysosomal compartments, ensuring consistent MHC class II presentation and Th1 immune response.

Exosomes deliver membrane-bound IL-21 to expand immune cells, eliminating feeder cell limitations.

A triple-mode yeast system matures, displays, and secretes antibodies simultaneously.

Segmented SMR peptides degrade biofilm matrices to expose drug-resistant bacteria for targeted antimicrobial action.

Synthetic peptides block CTLA4-B7 binding to enhance T cell activation while avoiding high antibody manufacturing costs.

A recombinant bacteriophage displays targeting ligands and foreign peptides on its capsid proteins to deliver genetic material.

Synthetic peptide capture agents bind botulinum neurotoxin serotype A to inhibit enzymatic activity and prevent SNAP-25 cleavage.

Codon-adapted ANAGO protein directs endonuclease activity to target DNA, resolving CRISPR off-target errors and sequence bias.

A fusion polypeptide incorporates a degradation domain that interacts with immunomodulatory imide drugs to regulate protein expression levels.

Soluble RAGE-Fc fusion proteins combine extracellular domains with immunoglobulin Fc regions to create stable therapeutic agents.

GPC3-specific CARs use a targeted scFv to recognize and destroy malignant cells while sparing normal tissue from off-target damage.

Temporary cell magnetization replaces expensive magnetic beads, reducing isolation costs while maintaining separation precision.

CIP2A-TOPBP1 inhibitors disrupt protein interactions to block cancer cell growth in homologous recombination deficient tumors.

A GLP-1-Fc fusion protein forms a stable tetramer structure to extend in vivo half-life.

RNA exporter proteins self-assemble into lipid-enveloped nanoparticles to secrete barcoded reporter RNA molecules from living cells.

Engineered lymphocytes overexpress anti-phagocytic signals to inhibit macrophage clearance and maintain therapeutic efficacy.

ICOS costimulation activates CD26high T cells to resolve the contradiction between reliable memory formation and tumor killing effectiveness.

Recombinant nucleic acid sequences encode defucosylated antibodies to overcome serum IgG competition and enhance in vivo efficacy.

Inserting modified heterologous sequences into the E-NS1 intergenic region maintains viral attenuation while expressing foreign antigens.

Chimeric antigen receptors guide mesenchymal stem cells to inflammatory sites, resolving the trade-off between systemic delivery and precise localization.

Segmenting the spacer into a stalk and extension region reduces dimerization sites to improve surface expression and antigen-binding efficiency.

Segmenting the Fc region into a single-chain format eliminates steric hindrance and maintains full bioactivity while extending serum half-life.

Nicotinamide supplementation during ex vivo expansion maintains NK cell homing and killing activity while increasing quantity for HER2 targeting.

A dual CAR T cell strategy employs a LAT intracellular signaling domain to enhance antigen recognition and cellular persistence.

Recombinant AAV vector encoding STC-1 delivers sustained intraocular pressure reduction, resolving patient compliance issues linked to daily eye drop regimens.